Recursion (RXRX) Q1 2026 earnings review
Burn Rate Decelerates as AI Platform Hits Clinical Milestones
Recursion is executing a textbook pivot from a cash-burning platform builder to a disciplined, clinical-stage TechBio company. The headline revenue decline ($6.5M vs $14.7M YoY) is noise driven by lumpy milestone timing. The real signal is the dramatic deceleration in cash burn: R&D expenses fell 32% YoY, and cash operating expenses dropped 30% to $85.1M. This financial discipline extends the cash runway into early 2028, buying crucial time for its AI-designed pipeline to mature. With the REC-1245 cancer program showing clean early safety data and REC-4881 heading to FDA registrational talks, the platform is finally yielding tangible clinical assets.
🐂 Bull Case
By cutting Q1 cash operating expenses by 30% YoY (from $120.2M to $85.1M), Recursion extended its cash runway to early 2028. This removes immediate dilution risk while the company advances five clinical programs.
Early data for REC-1245 (RBM39 degrader) showed no dose-limiting toxicities in solid tumors, validating the AI platform's ability to design safer molecules for historically toxic pathways.
🐻 Bear Case
The lead asset, REC-4881 for familial adenomatous polyposis (FAP), relies heavily on upcoming FDA engagement to define a registrational path. Any pushback on trial design or efficacy endpoints could derail timelines.
The company relies heavily on erratic partnership milestones to offset burn. Q1 2026 revenue fell 56% YoY simply because a major Roche milestone from the prior year did not repeat.
⚖️ Verdict: 🟢
Bullish. Management is doing exactly what the challenging macroeconomic environment demands: aggressively cutting costs to extend runway while advancing core clinical assets to tangible proof points.
Key Themes
Cost Structure Radically Improved
In response to macroeconomic challenges, management aggressively rationalized the portfolio post-Exscientia merger. R&D expenses decelerated sharply to $87.9M (down 32% YoY) and G&A dropped to $34.6M (down 37% YoY). This structural reset reduces reliance on capital markets and shields the company from biotech financing volatility.
REC-1245 Shows Clean Initial Safety
The Phase 1/2 DAHLIA study for REC-1245 (RBM39 degrader) is demonstrating a well-tolerated safety profile. Across 16 patients with solid tumors, 0% experienced Grade 4-5 adverse events, and no dose-limiting toxicities (DLTs) have been observed. This is a critical validation of the platform's ability to engineer specific, targeted degraders.
Foundation Models Gaining Superiority
Recursion's platform moat is deepening. The newly announced transcriptomics foundation model, TxFM, outperformed 16 leading models despite being trained on 100x less data than competitors. Additionally, TxPert was published in Nature Biotechnology, proving the AI can accurately predict cellular responses to unseen perturbations.
Revenue Trajectory Contradicts 'Momentum' Narrative
Management frequently cites 'growing joint portfolios' and partnership momentum, yet Q1 revenue decelerated massively, falling 56% YoY to $6.5M. This drop highlights a structural risk: until Recursion commercializes a drug, its top line is entirely at the mercy of unpredictable, binary partnership milestone achievements (like the missing Roche payout this quarter).
REC-4881 Regulatory Ambiguity
While Phase 2 data for REC-4881 in FAP was positive (43% median polyp reduction), the path to commercialization remains unclear. Management has initiated FDA engagement to define a potential registrational pathway, with an update expected in 2H26. Without a defined regulatory endpoint for this rare disease, commercial timelines are highly speculative.
Macro Context Mandates Perfection
Management explicitly noted that earlier portfolio cuts were driven by a 'challenging macroeconomic environment.' With $665.2M in cash against a ~$350M annualized burn, the margin for error is thin. A clinical failure in the REC-4881 or REC-1245 programs would severely pressure the stock before the 2028 runway is exhausted.
Other KPIs
Down sequentially from $753.9M at the end of 2025, but robust enough to secure the balance sheet into early 2028. The cash position ensures management does not need to negotiate from a position of weakness in future partnership deals or equity raises.
Accelerating efficiency. This is a massive improvement from the -$132.0M used in 25Q1. Management attributed this 38% reduction directly to the strategic reprioritization of the clinical portfolio and company-wide operating efficiencies.
Guidance
Stable. Management reiterated this guidance, which represents a structural deceleration from the pro forma burn rates seen in early 2024 prior to the Exscientia integration. This metric excludes partnership inflows, meaning any new milestones will directly extend the runway further.
Management expects to provide an update on FDA engagement regarding a registrational study design for FAP in the second half of 2026. This will be the next major binary catalyst for the stock.
Additional dose escalation data is expected. Investors will look to see if the drug can reach therapeutic exposures that trigger tumor regression without crossing the threshold into dose-limiting toxicities.
Key Questions
FDA Flexibility on FAP Endpoints
Given that there are no approved therapies for FAP, what specific surrogate endpoints (e.g., polyp burden reduction threshold) are you proposing to the FDA for the REC-4881 registrational trial?
REC-1245 Maximum Tolerated Dose
With no DLTs observed to date for REC-1245, how many more dose levels do you anticipate clearing before reaching the MTD, and are current exposures already hitting target efficacy levels?
Partnership Milestone Visibility
You achieved a $4M Sanofi milestone in Q1. Can you provide visibility on the cadence of the remaining expected partnership inflows needed to support the 'early 2028' cash runway guidance?